Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialYukio Kondo, Michèle Cavo, Robert M. Rifkin et al.|The Lancet Haematology|2019Cited by 247
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trialJong Wook Lee, Yasuo Mori, Jin Seok Kim et al.|The Lancet Haematology|2023Cited by 88